469 episodios
- In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate, and baclofen — for alcohol use disorder, examining their mechanisms, dosing strategies, tolerability challenges, and which patients are most likely to benefit when first-line treatments have failed.
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.25 CMEs: Pharmacotherapy of Alcohol Use Disorder
Gabapentin, Topiramate, and Baclofen for Alcohol Use Disorder - In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one of psychiatry's most effective drug classes? Dr. Scott Beach unpacks the risks, benefits, and clinical realities.
Faculty: Scott Beach, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 84
Benzodiazepine Tapering: Key Takeaways From New Guidelines - In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety considerations. Could enforced sobriety be the missing piece for your most treatment-resistant patients?
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder
Disulfiram for Alcohol Use Disorder: Mechanisms, Efficacy, and Hepatic Safety Considerations - In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the widely used GLP-1 receptor agonist, push lithium levels into toxic territory — and if so, why?
Faculty: Paul Zarkowski, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 83
Can GLP-1 Agonists Elevate Lithium Levels? - In this episode, we explore how naltrexone — the most widely used medication for alcohol use disorder in the US — works, how to dose it safely, and why liver disease may not be the barrier you think it is. Can a medication that doesn't target abstinence still be a game-changer for your patients?
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder
Naltrexone for Alcohol Use Disorder: Dosing, Monitoring, and Liver Safety
Más podcasts de Ciencias
Podcasts a la moda de Ciencias
Acerca de Psychopharmacology and Psychiatry Updates
Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.
Sitio web del podcastEscucha Psychopharmacology and Psychiatry Updates, Materia Oscura y muchos más podcasts de todo el mundo con la aplicación de radio.net

Descarga la app gratuita: radio.net
- Añadir radios y podcasts a favoritos
- Transmisión por Wi-Fi y Bluetooth
- Carplay & Android Auto compatible
- Muchas otras funciones de la app
Descarga la app gratuita: radio.net
- Añadir radios y podcasts a favoritos
- Transmisión por Wi-Fi y Bluetooth
- Carplay & Android Auto compatible
- Muchas otras funciones de la app


Psychopharmacology and Psychiatry Updates
Escanea el código,
Descarga la app,
Escucha.
Descarga la app,
Escucha.



































